Latest news & articles
Dexcom G6 CGM added to devices available through CGM Subsidy Initiative
The Dexcom G6 Continuous CGM system has been added to the devices available through the Australian Government’s CGM Subsidy Initiative.
Type 1 Diabetes Prevention: Promising Research Breakthrough Gives New Hope
A research breakthrough, funded by JDRF, has shown a promising future for the prevention of type 1 diabetes. Findings from a study by TrialNet show that the immunotherapy drug teplizumab can delay type 1 diabetes diagnosis a median of 2 years in children and adults at high risk. The study showed that teplizumab interferes with […]
Snacking 101: An explainer for people living with type 1 diabetes
Right now, we’re in our houses more than ever before. We work, learn, sleep and socialise in our house. That’s a lot of time inside! You’ve probably found as social distancing restrictions are easing that you’ve developed some habits which make managing type 1 diabetes trickier because you’ve been cooped up indoors. Stuff like staying up late and sleeping in, trouble […]
Emerging from the COVID cocoon: Strategies for families newly diagnosed with T1D
This content was co-written by Simone Collins, Diabetes Social Worker at Canberra Health Services and Melanie Cullen, Paediatric Psychologist and Insulin Pump Program Coordinator at JDRF Australia for families of children newly diagnosed with T1D. The outbreak of COVID-19 has impacted people in all walks of life on an international scale. Our lives have been […]
So, What is Kids In The House Anyway?
If you have been following JDRF across our social channels, or have been speaking to any of our diligent advocates, you may have heard of Kids in the House. Curious as to what it is? And how you can support? Then read on! What is Kids in the House? Kids in the House is the […]
When Did You Last Have Your Eyes Checked?
The JDRF-led Type 1 Diabetes Clinical Research Network is currently recruiting for a study which could help reduce eye complications for people with type 1 diabetes. See full study details here, or email the FAME-1 study team at email@example.com.